Norgine licenses Santarus's immediate-release omeprazole in Europe
This article was originally published in Scrip
The speciality pharma company Norgine has licensed exclusive development, manufacturing and commercialisation rights to Santarus's immediate-release omeprazole product, Zegerid, in certain Western, central and Eastern European markets. Norgine will pay Santarus $2.5 million up front and up to $10 million in milestones related to regulatory achievements. It will also pay tiered royalties in the mid- to high-teens. Norgine's payments may be reduced for certain reasons, including costs it incurs in obtaining regulatory approval or reimbursement in major markets.